6489 LOGO20THELANSIS 8

Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today presents long-term safety and efficacy data from the open-label extension (OLE) of its global Phase 3 MPOWERED non-inferiority clinical trial that compared Mycapssa® (oral octreotide capsules) to long-acting iSRLs for maintenance of biochemical response in patients with acromegaly. The MPOWERED trial was designed to support the marketing authorization application for Mycapssa® by the EMA which is currently under evaluation. Mycapssa® is approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide. Source: Amryt Pharma plc

 

Acromegaly-forecast

 

Based on the Thelansis market insight report on Acromegaly, which provides a clear understanding on disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.

https://thelansis.com/reports/acromegaly-market-outlook-report/

The overall annual incidence rate of Acromegaly was relatively varying between 11 to 23 cases per million population in the USA. 

          

Worldwide coverage

 

Comprehensive insight on patient segmentation based on Origin (Pituitary Tumor & Non-Pituitary Tumor), Adenoma size (Macroadenomas and Microadenomas), responsive to treatment (Surgical & Non-surgical), Clinical Manifestations (osteoarticular manifestation, cardiovascular manifestation, respiratory manifestations, gastrointestinal manifestation, endocrinological and other manifestations) has been provided into the epidemiology (Incidence and Prevalence) section of the Acromegaly and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

 

KOL database for PMR

https://thelansis.com/kol-database-access/

 

In terms of pharmacologic therapies, Several drug candidates are in Phase II and II/ III stages of development by various companies. Key assets among these are, CAM2029; Novartis, Mycapssa; Chi-asma, ATL1103; Antisense Therapeutics, COR-005 (Veldoreotide); Strongbridge Biopharma, CRN00808; Crinetics Pharmaceuticals, IONIS-GHR-LRx; Ionis Pharmaceuticals. Among these key assets, some of the assets are being designated as orphan drugs and EMA and US FDA.

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-

Charcot-Marie-Tooth (CMT) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Acute Kidney Injury (AKI)  – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030 – 2020 To 2030

Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report  – 2020 To 2030

Epidermolysis Bullosa (EB) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Familial Amyloid Polyneuropathy (FAP) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report– 2019 To 2030

 

Tags: Epidermolysis Bullosa, Charcot-Marie-Tooth, CMT, Acute Kidney Injury, AKI, Cushing’s Syndrome, Familial Amyloid Polyneuropathy (FAP), CAM2029, ATL1103, Antisense Therapeutics, COR-005, Veldoreotide, Strongbridge Biopharma, CRN00808, Crinetics Pharmaceuticals, lanreotide

See Campaign: https://thelansis.com/reports/
Contact Information:
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India Contact no.: +91(124) 404-1731 Sales office 183-Asylum Street Hartford, CT-06103, USA USA +1 (267) 244-6955, Email clientsupport@thelansis.com m.berg@thelansis.com

Tags:
PR-Wirein, Menafn, Reportedtimes, iCN Internal Distribution, Research Newswire, English